| Literature DB >> 24966868 |
Amy C Lossie1, William M Muir2, Chiao-Ling Lo3, Floyd Timm3, Yunlong Liu4, Whitney Gray3, Feng C Zhou5.
Abstract
Maternal alcohol consumption inflicts a multitude of phenotypic consequences that range from undetectable changes to severe dysmorphology. Using tightly controlled murine studies that deliver precise amounts of alcohol at discrete developmental stages, our group and other labs demonstrated in prior studies that the C57BL/6 and DBA/2 inbred mouse strains display differential susceptibility to the teratogenic effects of alcohol. Since the phenotypic diversity extends beyond the amount, dosage and timing of alcohol exposure, it is likely that an individual's genetic background contributes to the phenotypic spectrum. To identify the genomic signatures associated with these observed differences in alcohol-induced dysmorphology, we conducted a microarray-based transcriptome study that also interrogated the genomic signatures between these two lines based on genetic background and alcohol exposure. This approach is called a gene x environment (GxE) analysis; one example of a GxE interaction would be a gene whose expression level increases in C57BL/6, but decreases in DBA/2 embryos, following alcohol exposure. We identified 35 candidate genes exhibiting GxE interactions. To identify cis-acting factors that mediated these interactions, we interrogated the proximal promoters of these 35 candidates and found 241 single nucleotide variants (SNVs) in 16 promoters. Further investigation indicated that 186 SNVs (15 promoters) are predicted to alter transcription factor binding. In addition, 62 SNVs created, removed or altered the placement of a CpG dinucleotide in 13 of the proximal promoters, 53 of which overlapped putative transcription factor binding sites. These 53 SNVs are also our top candidates for future studies aimed at examining the effects of alcohol on epigenetic gene regulation.Entities:
Keywords: epigenetics; fetal alcohol syndrome; gene expression; gene x environment interactions; genetic association; genomics; next generation sequencing
Year: 2014 PMID: 24966868 PMCID: PMC4052096 DOI: 10.3389/fgene.2014.00173
Source DB: PubMed Journal: Front Genet ISSN: 1664-8021 Impact factor: 4.599
Figure 1Summary of the differentially expressed genes. (A) Line-specific differences in gene expression. We conducted this analysis in two separate experiments that captured two embryonic phenotypes: neural tube closed (NTC) and neural tube open (NTO). This analysis was conducted by examining the gene expression changes solely between C57BL/6NHsd and DBA/2NHsd; alcohol exposure is not taken into consideration. Therefore, in the NTC group, all C57BL/6NHsd embryos (with and without alcohol) were measured as one cohort, while the DBA/2NHsd embryos (with and without alcohol) comprised the second group. The NTO cohort was analyzed in the same manner. This depicts the innate changes in gene expression between the two genetic backgrounds, plus the changes that are due to alcohol exposure, but cannot assess if there are interactions between the genetic background and alcohol exposure. There are 1403 genes that are differentially expressed between the C57BL/6NHsd and DBA/2NHsd embryos; 904 of these are differentially expressed in both the NTO and NTC studies. (B) Differential gene expression as result of genetic and alcohol interactions (GxE). As above, we analyzed gene expression in the NTC and NTO cohorts separately. In this study, we measured the potential interactions between alcohol exposure and genetic background. We found 22 genes that demonstrated GxE interactions in the NTC group and 13 genes showing GxE interactions in the NTO group. (C) Genes subject to GxE Interactions. The genes subject to GxE interactions are delineated.
Networks of NTO/NTC overlapping genes between C57BL/6NHsd and DBA/2NHsd.
| 50 | 32 | Inflammatory Response, Cellular Function and Maintenance, Cellular Movement | |
| 40 | 28 | Cellular Compromise, Cellular Function and Maintenance, Cell Death and Survival | |
| 34 | 25 | Embryonic Development, Organ Development, Organismal Development |
Genes Demonstrating a GxE Interaction with Associated SNVs in the Promoter.
| Tyrosine phosphatase, transcription activator | Cranial placodes, branchial arches and CNS during organogenesis | Regulate preplacedal ectoderm (PPE) differentiation | Xu et al., | ||
| Hydrolyzing O-glycosyl compounds | E14.5 to adult—Cardiovascular and nervous system (mainly in human adult and fetal brains) | Candidate gene for Autism Spectrum Disorders (ASDs) | Shimizu et al., | ||
| Transfer a malonyl group from malonyl-CoA to the mitochondrial acyl carrier protein | E14.5 by RT-PCR | N/A | Smith et al., | ||
| Neural peptide signaling | E11.5 to adult—CNS | May involve pain modulation | Mar et al., | ||
| Transport of endosomes to the trans-Golgi network (TGN) | N/A | N/A | Skarnes et al., | ||
| Angiogenesis and activity-dependent changes of brain vasculature | E14.5—Heart ventricle | May affect blood-brain permeability | Diez-Roux et al., | ||
| Gene transcription regulation and chromatin remodeling | E9.5, E11.5, and E14.5—urogenital system | Cardiac and neural crest development in zebrafish | Wertz and Herrmann, | ||
| Proteasome activator, involves in histone degradation and DNA damage response | E14.5—Nervous system, sensory organs, alimentary system, and skeletal system | N/A | Ustrell et al., | ||
| VIP receptor, modulated by G-proteins | E12-E18.5 by RT-PCR; detected at | Promote neuronal survival | Delgado et al., | ||
| E13.5—cerebral cortex; Adult rat: cerebral cortex and hippocampus | |||||
| Membrane protein of unknown function | E14.5—alimentary system, limbs, head, skeleton system, sensory organs | Deleted in a patient with behavioral disturbance, autism, and epilepsy. | Diez-Roux et al., | ||
| Infection, inflammation, regulation of cell proliferation and apoptosis | Post-natal brain, testis and adipose tissue | N/A | Diez-Roux et al., | ||
| Vitamin B6 Metabolism | E14.5—Nervous system, sensory organs, cardiovascular system, alimentary system | Activates cofilin through dephosphorylation | Niwa et al., | ||
| Required for normal progress through mitosis and normal cytokinesis. | |||||
| Structural constituent of ribosome | E2 to E4.5—blastocyst | Down-regulated in spinal cord of Amyotrophic Lateral Sclerosis (ALS) model | de Oliveira et al., | ||
| E12.5 to E18.5—brain | |||||
| Regulation of cell development, activation, growth and motility | E14.5—pituitary | Involved in early differentiation of oligodendrocytes | Birling et al., | ||
| Post-natal—CNS | |||||
| Stat6-regulated KRAB domain zinc finger protein, binds DNA and regulate transcription | E8.5—head fold, neural tube at mid-gestation—brain, neural tube, mammary placodes, limbs | Oliver et al., | |||
| 2′O-ribose methylation of RNA | N/A | N/A | Nicoloso et al., |
Figure 2. The Affymetrix PLIER expression levels are shown on the Y-axis. The black circles represent gene expression levels in control embryos, while the triangles represent gene expression levels in the alcohol-treated animals. Two conditions are measured in this experiment, gene expression levels in controls and gene expression levels in EtOH-treated animals. The blue line depicts the changes in gene expression found between the C57BL/6NHsd control embryos (black circle) and their EtOH-treated test embryos (black triangle). The red line depicts the changes in in gene expression found between the DBA/2NHsd control embryos (black circle) and their EtOH-treated test embryos (black triangle). The interaction is depicted by showing an inverse correlation between the gene expression profiles of the two inbred strains.
SNVs near .
| 1 | 165417649 | Promoter | Promoter | Promoter | N/A | N/A | GTGTACATGG[T/C]ATATGTATGG | T | 100 | C | 100 | T | ||
| 2 | rs33341731 | 165419967 | Promoter | Promoter | Promoter | CG/CA | Hes1 | Hoxa5/Hes1 | GAAACCTTGC[G/A]TTGGGGGGTG | G | 100 | A | 100 | G |
| 3 | 165429834 | Intron 1 | Promoter | Promoter | SRF | N/A | TATAACCCGA[G/A]CTTAAAGGCC | G | 100 | A | 100 | G | ||
| 4 | rs33448850 | 165431347 | Intron 1 | Promoter | Promoter | CG/TG | N/A | TFE3-S/c-Fos | TATACTCACA[C/T]GAAAAAAAAC | C | 100 | T | 100 | C |
| 5 | 165465686 | Intron 1 | Promoter | Promoter | C/EBPbeta | c-Fos | ACACACACAC[A/T]CACACACACA | A | 100 | T | 100 | A | ||
| 6 | 165466018 | Intron 1 | Promoter | Promoter | C/EBPbeta c-Fos | TCF-1(P) c-Fos | TCTCTCTCTC[A/T]CACACACACA | A | 100 | T | 100 | A | ||
| 7 | 165475306 | Intron 1 | Promoter | Promoter | N/A | C/EBPbeta | GGGATGGAGG[G/A]CAGATAAGAA | G | 100 | A | 100 | G | ||
| 8 | 165475312 | Intron 1 | Promoter | Promoter | GATA-1 | Tal-1 RelA | GAGGGCAGAT[AA/GG]GAAGGGACA | A | 100 | G | 100 | A | ||
| GATA-2 | NF-kappaB COE1 | |||||||||||||
| 9 | 165475313 | Intron 1 | Promoter | Promoter | A | 100 | T | 100 | A | |||||
| 10 | 165475318 | Intron 1 | Promoter | Promoter | N/A | TCF-1(P); | AGATAAGAAG[G/A]GACAGGGAGA | G | 100 | A | 100 | G | ||
| 11 | 165475328 | Intron 1 | Promoter | Promoter | TCF-1(P) | c-Fos DEC2 | GGACAGGGAG[A/G]TGAATGGGAT | A | 100 | G | 100 | A | ||
| 12 | rs27298255 | 165485303 | Intron 1 | Intron 1 | Promoter | N/A | HES-1 myogenin | GTGTTAACAG[G/C]AAGTTGTGAA | G | 100 | C | 100 | G | |
| MyoD | ||||||||||||||
| 13 | 165485789 | Intron 1 | Intron 1 | Promoter | N/A | N/A | CCACCACCAC[T/C]ATACAAAGGA | T | 100 | C | 100 | T | ||
| 14 | 165486306 | Intron 1 | Intron 1 | Promoter | TCF-1(P) | C/EBPbeta | CTCTCTCTCT[C/G]TGTGTGTGTG | C | 100 | G | 100 | C | ||
| TCF-1(P) | ||||||||||||||
| 15 | 165488467 | Intron 1 | Intron 1 | Promoter | N/A | c-Fos DEC2 | AGATGGGTTG[G/A]AGCTAGCCTG | G | 100 | A | 100 | G | ||
| 16 | 165488503 | Intron 1 | Intron 1 | Promoter | GG/CG | LyF-1 | LyF-1 | GTCGTTGTTT[G/C]GGGAGAAATC | G | 100 | C | 100 | G | |
| 17 | rs3718350 | 165488796 | Intron 1 | Intron 1 | Promoter | GR | TCF-1(P) | CTTAACAAGA[A/G]CAGTATGCAC | A | 100 | G | 100 | A | |
| C/EBPbeta | ||||||||||||||
| 18 | rs27298227 | 165489658 | Intron 1 | Intron 1 | Promoter | TFE3-S | TFE3-S | GTCTCACATG[GG/CA]TAAGGCAAGA | G | 100 | C | 100 | G | |
| 19 | 165489659 | Intron 1 | Intron 1 | Promoter | G | 100 | A | 100 | G | |||||
| 20 | rs27298226 | 165489698 | Intron 1 | Intron 1 | Promoter | CG/CA | TCF-1(P) | c-Fos | TAGCCCTCTC[G/A]GTACTTAGCA | G | 100 | A | 100 | G |
| TCF-1(P) | ||||||||||||||
| 21 | rs27298225 | 165489830 | Intron 1 | Intron 1 | Promoter | CG/AG | HES-1 | HES-1 | AAGGCACTTG[C/A]GAAACAGTAT | C | 100 | A | 100 | C |
| Nkx2-1 | Nkx2-1 c-Fos | |||||||||||||
Summary of the potential regulatory effects of the SNVs between C57BL/6NJ and DBA/2J in genes demonstrating GxE interactions.
| NTC | CUB and Sushi multiple domains 3 | 15 | 47412184-48623535 | Reverse | 11 | 8 | 1 | 0 | 1 | 1 | |
| NTC | Eyes Absent | 2 | 165420528-165597131 | Forward | 21 | 16 | 5 | 4 | 1 | 4 | |
| Homolog2 (Drosophila) | |||||||||||
| NTC | Membrane protein | 7 | 80885193-80921805 | Forward | 1 | 0 | 0 | 0 | 0 | 0 | |
| FAM174B precursor | |||||||||||
| NTC | Melanoma-associated antigen | X | 89364218-89844911 | Forward | 1 | 1 | 0 | 0 | 0 | 0 | |
| B18 | |||||||||||
| NTC | Malonyl CoA:ACP | 15 | 83377227-83386141 | Reverse | 54 | 42 | 12 | 6 | 5 | 9 | |
| Acyltransferase | |||||||||||
| (Mitochondrial) | |||||||||||
| NTC | Pyridoxal phosphate phosphatase | 15 | 78744349-78749947 | Forward | 18 | 14 | 9 | 5 | 4 | 8 | |
| NTC | 60S ribosomal protein L36a | X | 131120193-131122601 | Forward | 3 | 2 | 1 | 1 | 0 | 1 | |
| NTC | Tachykinin-2 | 10 | 127162448-127168824 | Forward | 9 | 7 | 3 | 1 | 2 | 3 | |
| NTC | Tetraspanin-2 | 3 | 102538693-102576233 | Forward | 1 | 1 | 0 | 0 | 0 | 0 | |
| NTC | Zinc finger protein 157 | 5 | 138882704-138901922 | Forward | 5 | 3 | 2 | 2 | 0 | 1 | |
| NTO | Apolipoprotein L | 6 | 134932019-134936854 | Forward | 51 | 43 | 12 | 6 | 6 | 11 | |
| Domain Containing 1 | |||||||||||
| NTO | Paf1/RNA | 9 | 75289331-75314239 | Forward | 6 | 6 | 3 | 1 | 2 | 3 | |
| Polymerase II | |||||||||||
| Complex Component | |||||||||||
| NTO | Proteasome (Prosome, Macropain) Activator | 11 | 30671775-30780361 | Forward | 16 | 10 | 2 | 1 | 1 | 2 | |
| Subunit 4 | |||||||||||
| NTO | Small nucleolar RNA, C/D box 38A | 4 | 116827121-116827179 | Reverse | 32 | 24 | 8 | 4 | 3 | 7 | |
| NTO | Vasoactive Intestinal | 9 | 121551834-121582072 | Forward | 8 | 6 | 3 | 2 | 1 | 2 | |
| Peptide Receptor 1 | |||||||||||
| NTO | Vacuolar protein sorting 51 | 19 | 6067842-6077187 | Reverse | 4 | 3 | 1 | 1 | 0 | 1 | |
| Total | 241 | 186 | 62 | 34 | 26 | 53 | |||||